Alon Ben-Noon is the Co-founder and CEO, of NeuroSense Therapeutics, a drug development company focusing on the treatment of ALS and other neurodegenerative diseases. *This interview was conducted in January of 2022*Since the interview, NeuroSense successfully concluded additional biomarker experiments of ALS and Alzheimer's disease. In addition, the company commenced a Phase IIb clinical trial in ALS (Paradigm Study) and enrolled several patients with the aim to complete enrollment by ...
All content for HealthTech Israel Podcast is the property of Chen Sirkis and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Alon Ben-Noon is the Co-founder and CEO, of NeuroSense Therapeutics, a drug development company focusing on the treatment of ALS and other neurodegenerative diseases. *This interview was conducted in January of 2022*Since the interview, NeuroSense successfully concluded additional biomarker experiments of ALS and Alzheimer's disease. In addition, the company commenced a Phase IIb clinical trial in ALS (Paradigm Study) and enrolled several patients with the aim to complete enrollment by ...
Lena Levin is the CEO and co-founder of Via Surgical. Her previous venture PolyTouch Medical was acquired in 2011.She has managed to raise tens of millions of dollars over the years with private investors and Israel innovation, and in her not so she mentors early-stage startups and different accelerators.Here is a summary of the interview: 01:20 How do four students with a schnitzel end up founding a medical devices company?03:...
HealthTech Israel Podcast
Alon Ben-Noon is the Co-founder and CEO, of NeuroSense Therapeutics, a drug development company focusing on the treatment of ALS and other neurodegenerative diseases. *This interview was conducted in January of 2022*Since the interview, NeuroSense successfully concluded additional biomarker experiments of ALS and Alzheimer's disease. In addition, the company commenced a Phase IIb clinical trial in ALS (Paradigm Study) and enrolled several patients with the aim to complete enrollment by ...
